TY - JOUR
T1 - Changes in HPV16/18 Prevalence among Unvaccinated Women with Cervical Intraepithelial Neoplasia in Japan
T2 - Assessment of Herd Effects following the HPV Vaccination Program
AU - for the MINT Study Group
AU - Onuki, Mamiko
AU - Yamamoto, Kasumi
AU - Yahata, Hideaki
AU - Kanao, Hiroyuki
AU - Horie, Koji
AU - Konnai, Katsuyuki
AU - Nio, Ai
AU - Takehara, Kazuhiro
AU - Kamiura, Shoji
AU - Tsuda, Naotake
AU - Takei, Yuji
AU - Shigeta, Shogo
AU - Nakai, Hidekatsu
AU - Yoshida, Hiroyuki
AU - Motohara, Takeshi
AU - Kato, Tatsuya
AU - Nakamura, Keiichiro
AU - Hamanishi, Junzo
AU - Tasaka, Nobutaka
AU - Ishikawa, Mitsuya
AU - Kado, Nobuhiro
AU - Taira, Yusuke
AU - Mori, Mayuyo
AU - Iwata, Takashi
AU - Takahashi, Fumiaki
AU - Kukimoto, Iwao
AU - Yoshikawa, Hiroyuki
AU - Yaegashi, Nobuo
AU - Matsumoto, Koji
N1 - Funding Information:
Funding: This work was supported by grants obtained from the Foundation for Advancement of International Science (FAIS), the Japan Agency of Medical Research and Development (AMED) (grant number: JP21fk0108098) and JSPS KAKENHI (grant number: JP20K09677). The supporting organizations played no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript.
Funding Information:
This work was supported by grants obtained from the Foundation for Advancement of International Science (FAIS), the Japan Agency of Medical Research and Development (AMED) (grant number: JP21fk0108098) and JSPS KAKENHI (grant number: JP20K09677). The supporting organizations played no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript. Acknowledgments: On behalf of monitoring the impact of HPV vaccination and HPV genotype-specific disease incidence in Japan study group. We thank Shido Inc. (https://shido.co.jp, accessed on 10 January 2022) for research support and Edanz (http://jp.edanz.com/ac, accessed on 10 January 2022) for editing a draft of this manuscript.
Publisher Copyright:
© 2022 by the authors. Licensee MDPI, Basel, Switzerland.
PY - 2022/2
Y1 - 2022/2
N2 - Since the human papillomavirus (HPV) vaccination program for Japanese girls aged 12–16 years began in 2010, vaccination uptake has been low in women born before 1993 but high (approximately 70%) in those born during 1994–1999. We previously compared the prevalence of vaccine types HPV16 and HPV18 in cervical intraepithelial neoplasia grade 1–3 (CIN1–3) or adenocarcinoma in situ (AIS) between vaccinated and unvaccinated cohorts and found direct protection effects among vaccinated women in Japan. In this study, we focused on changes in HPV16/18 prevalence among “unvaccinated” cohorts with CIN/AIS. We analyzed HPV16/18 prevalence among 5051 unvaccinated women aged <40 years, newly diagnosed with CIN/AIS during 2012–2021 for time trends. Declining trends in HPV16/18 prevalence over 9 years were observed in CIN1 (36.0–10.0%, Ptrend = 0.03) and CIN2–3/AIS (62.5–36.4%, Ptrend = 0.07) among women aged <25 years. HPV16/18 prevalence in CIN1 and CIN2–3/AIS diagnosed at age 20–24 years was lower in 1994–1999 birth cohorts compared with 1988–1993 birth cohorts (4.5% vs. 25.7% for CIN1 and 40.0% vs. 58.1% for CIN2–3/AIS, both p = 0.04). Significant reduction in HPV16/18 prevalence among young unvaccinated women with CIN1 and CIN2–3/AIS suggests herd effects of HPV vaccination in Japan.
AB - Since the human papillomavirus (HPV) vaccination program for Japanese girls aged 12–16 years began in 2010, vaccination uptake has been low in women born before 1993 but high (approximately 70%) in those born during 1994–1999. We previously compared the prevalence of vaccine types HPV16 and HPV18 in cervical intraepithelial neoplasia grade 1–3 (CIN1–3) or adenocarcinoma in situ (AIS) between vaccinated and unvaccinated cohorts and found direct protection effects among vaccinated women in Japan. In this study, we focused on changes in HPV16/18 prevalence among “unvaccinated” cohorts with CIN/AIS. We analyzed HPV16/18 prevalence among 5051 unvaccinated women aged <40 years, newly diagnosed with CIN/AIS during 2012–2021 for time trends. Declining trends in HPV16/18 prevalence over 9 years were observed in CIN1 (36.0–10.0%, Ptrend = 0.03) and CIN2–3/AIS (62.5–36.4%, Ptrend = 0.07) among women aged <25 years. HPV16/18 prevalence in CIN1 and CIN2–3/AIS diagnosed at age 20–24 years was lower in 1994–1999 birth cohorts compared with 1988–1993 birth cohorts (4.5% vs. 25.7% for CIN1 and 40.0% vs. 58.1% for CIN2–3/AIS, both p = 0.04). Significant reduction in HPV16/18 prevalence among young unvaccinated women with CIN1 and CIN2–3/AIS suggests herd effects of HPV vaccination in Japan.
KW - Adenocarcinoma in situ
KW - Cervical cancer
KW - Cervical intraepithelial neoplasia
KW - Human papillomavirus
KW - Vaccination
UR - http://www.scopus.com/inward/record.url?scp=85124017783&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85124017783&partnerID=8YFLogxK
U2 - 10.3390/vaccines10020188
DO - 10.3390/vaccines10020188
M3 - Article
AN - SCOPUS:85124017783
SN - 2076-393X
VL - 10
JO - Vaccines
JF - Vaccines
IS - 2
M1 - 188
ER -
